Pharmaceutical care (PC) is a process through which a pharmacist works with other healthcare professionals and the patient to optimise pharmacotherapy. Early studies, carried out before PC was established, provided limited evidence of the benefits of pharmacist involvement in diabetes management. More recent research has examined the role of PC in a range of diabetic sub-groups. Although few of these studies were randomised, prospective and included clinically important end points such as HbA1C, some beneficial effects of PC were reported. In the most recent study, a 12-month randomised controlled trial of PC in community-based diabetic patients, regular face-to-face and telephone interviews with an experienced clinical pharmacist improved glycosylated haemoglobin while glycaemic control did not change in the controls. In addition, reductions in blood pressure, and in absolute vascular risk for patients with no history of coronary artery disease, were significantly greater in the PC group. Available evidence suggests that PC can prove a valuable component of community-based multi-disciplinary diabetes care.
Hepler CD, Strand LMOpportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm1990;47:533-43.
3.
Knowlton CH, Thomas OV, Williamson A. et al. Establishing community pharmacy-based anticoagulation education and monitoring programs. J Am Pharm Assoc1999;39:368-74.
4.
Kennie NR, Schuster BG, Einarson TRCritical analysis of the pharmaceutical care research literature. Ann Pharmacother1998;32:17-26.
5.
Sczupak CA, Conrad WFRelationship between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. Am J Hosp Pharm1977;34:1238-42.
6.
Hawkins DW, Fiedler FP, Douglas HL, Eschbach RCEvaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm1979;36:1321-5.
7.
Jaber LA, Halapy H., Fernet M., Tummalapalli S., Diwakaran H.Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother1996;30:238-43.
8.
Halapy H., Jaber LADiabetes management: follow-up. Ann Pharmacother1997;31:371.
9.
Coast-Senior E., Kroner B., Kelley C., Trilli L.Management of patients with type 2 diabetes by pharmacists in primary care clinics. Am J Health Syst Pharm1998;55:638-41.
10.
Baran RW, Crumlish K., Patterson H. et al. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counselling. Am J Health Syst Pharm1999;56:1535-9.
11.
Kelly C., Rodgers PTImplementation and evaluation of a pharmacist-managed diabetes service . J Manag Care Pharm2000;6:488-93.
12.
Odegard PS, Goo A., Hummel J., Williams KL, Gray SLCaring for poorly controlled diabetes mellitus: a randomized pharmacist intervention . Ann Pharmacother2005;39:433-40.
13.
Cooper J.Consultant pharmacist contribution to diabetes mellitus patients outcomes in two nursing facilities. Consult Pharm1995 ;10:40-5.
14.
Veldhuizen-Scott M., Widmer L., Stacey F., Popovich N.Developing and implementing a pharmaceutical care model in an ambulatory care setting for patients with diabetes. Diab Educ1995;21:117-23.
15.
Wermeille J. , Bennie M., Brown I., McKnight J.Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team - a pilot study. Pharm World Sci2004 ;26:18-25.
16.
Cranor C., Bunting B., Christensen D.The Asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc2003;43:173-84.
17.
Irons BK, Lenz RJ, Anderson SL, Wharton B., Habeger B., Anderson G.A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic . Pharmacotherapy2002;22:1294-300.
18.
Clifford RM , Batty KT, Davis TM et al. A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. Int J Pharm Pract2002;10:85-9.
19.
Clifford RM , Batty KT, Davis WA, Davis TMEffect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. Diabetes Care2005;28:771-6.
20.
Davis TM, Zimmet P., Davis WA, Bruce D., Fida S., Mackay I.Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med2000;17:667-74.
21.
Bruce DG, Davis WA, Davis TMGlycemic control in elderly subjects with type 2 diabetes mellitus in the Fremantle Diabetes Study. J Am Geriatr Soc2000;48:1449-53.
22.
Stevens RJ, Kothari V., Adler AI, Stratton IMfor the United KingdomProspective Diabetes Study(UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci2001;101:671-9.
